Trinodal Self-Penetrating Versus cds 3-Dimensional Networks Using Bis(3,2' : 6',3''-terpyridine) Building Blocks: the Solvent Makes the Difference

Reactions between Co(NCS)2 and 24,24-[2,5-bis(cyclohexyloxy)-1,4-phenylene]di(13,22 :26,33-terpyridine) (1), 24,24-[2,5-bis(cyclohexylmethoxy)-1,4-phenylene]di(13,22 :26,33-terpyridine) (2), and 24,24-[2,5-bis(2-phenylethoxy)- 1,4-phenylene]di(13,22 :26,33-terpyridine) (3) under conditions of crystal growth by layering at room temperature lead to 3-dimensional nets with either a cds or trinodal self-penetrating topology depending upon the solvents (MeOH/C6H5Cl, MeOH/1,2-Cl2C6H5, or MeOH/CHCl3) used in the crystallization experiments. The cds network was found for [Co(NCS)2(1)]n.2nC6H4Cl2, [Co(NCS)2(2)]n.4nC6H4Cl2, and [Co(NCS)2(3)]n.2.5nC6H5Cl, while a trinodal selfpenetrating net was observed in [Co2(NCS)4(2)2]n.5.5nCHCl3.0.2nMeOH. Preliminary structural data for single crystals from the reactions of Co(NCS)2 and 1 or Co(NCS)2 and 3 from MeOH/CHCl3 solvent combinations also evidenced the assemblies of trinodal self-penetrating nets. Both net topologies assemble from a combination of planar, 4-connecting metal and ligand nodes. The role of the solvent in directing the network type is investigated

Isomeric 4,2′:6′,4″- and 3,2′:6′,3″-Terpyridines with Isomeric 4′-Trifluoromethylphenyl Substituents: Effects on the Assembly of Coordination Polymers with [Cu(hfacac)2] (Hhfacac = Hexafluoropentane-2,4-dione)

The isomers 4′-(4-(trifluoromethyl)phenyl)-4,2′:6′,4″-terpyridine (1), 4′-(3-(trifluoromethyl) phenyl)-4,2′:6′,4″-terpyridine (2), 4′-(4-(trifluoromethyl)phenyl)-3,2′:6′,3″-terpyridine (3), and 4′-(3-(trifluoromethyl)phenyl)-3,2′:6′,3″-terpyridine (4) have been prepared and characterized. The single crystal structures of 1 and 2 were determined. The 1D-polymers [Cu2(hfacac)4(1)2]n.2nC6H4Cl2 (Hhfacac = 1,1,1,5,5,5-hexafluoropentane-2,4-dione), [Cu(hfacac)2(2)]n.2nC6H5Me, [Cu2(hfacac) 4(3)2]n.nC6H4Cl2, [Cu2(hfacac)4(3)2]n.nC6H5Cl, and [Cu(hfacac)2(4)]n.nC6H5Cl have been formed by reactions of 1, 2, 3 and 4 with [Cu(hfacac)2].H2O under conditions of crystal growth by layering and four of these coordination polymers have been formed on a preparative scale. [Cu2(hfacac) 4(1)2]n.2nC6H4Cl2 and [Cu(hfacac)2(2)]n.2nC6H5Me are zig-zag chains and the different substitution position of the CF3 group in 1 and 2 does not affect this motif. Packing of the polymer chains is governed mainly by C-F...F-C contacts, and there are no inter-polymer π-stacking interactions. The conformation of the 3,2′:6′,3″-tpy unit in [Cu2(hfacac)4(3)2]n.nC6H4Cl2 and [Cu(hfacac)2(4)]n.nC6H5Cl differs, leading to different structural motifs in the 1D-polymer backbones. In [Cu(hfacac) 2(4)]n.nC6H5Cl, the peripheral 3-CF3C6H4 unit is accommodated in a pocket between two {Cu(hfacac) 2} units and engages in four C-Hphenyl...F-Chfacac contacts which lock the phenylpyridine unit in a near planar conformation. In [Cu2(hfacac)4(3)2]n.nC6H4Cl2 and [Cu(hfacac)2(4)]n.nC6H5Cl, π-stacking interactions between 4′-trifluoromethylphenyl-3,2′:6′,3″-tpy domains are key packing interactions, and this contrasts with the packing of polymers incorporating 1 and 2. We use powder X-ray diffraction to demonstrate that the assemblies of the coordination polymers are reproducible, and that a switch from a 4,2′:6′,4″- to 3,2′:6′,3″-tpy metal-binding unit is accompanied by a change from dominant C-F...F-C and C-F...H-C contacts to π-stacking of arene domains between ligands 3 or 4

Performance of Delta4 Phantom+ using Flattening-Filter and Flattening Filter-Free beams

EnThe goal of this study was to evaluate the performances of the new pre-treatment system Delta4 Phantom+ in terms of a stable and sensitive tool for achieving a reliable verification. Delta4+ was evaluated for verification with 6FFFMV beams using static beam arrangement. The accelerator output was monitored with the ionization chamber. The device was tested for dose-rate dependence, linearity and stability using its daily output correction. The response of Delta4+ was evaluated for energy 6FFFMV, measuring the gamma index of four Volumetric Modulated Arc Therapy (VMAT) plan. The response of Delta4+ as a function of accelerator dose rate is in agreement with the ionization chamber with a difference smaller than 0,1%. The output is constant for different MU. VMAT plan analysis show values within 98,3%-100% with a threshold of 3%-3mm, while with a threshold of 2%-2mm the values are within 93,5%-97,5%. Delta4+ is an accurate device. For all the measurements made, uncertainties below 1% were obtained.ItLo scopo di questo studio è stato quello di valutare la risposta in termini di stabilità e sensibilità del nuovo sistema pre-trattamento Delta4 Phantom+. La risposta del sistema è stato studiata utilizzando fasci di fotoni da 6MVsenza filtro di flattening (6FFFMV). L'output dell'acceleratore è stato monitorato con una camera a ionizzazione. La dipendenza dal dose rate, la linearità e la stabilità sono state verificate utilizzando il fattore di correzione giornaliera fornito dal sistema. La risposta è stata verificata su 4 piani di trattamento con tecnica VMAT. La risposta del Delta4+ al variare del dose rate è in accordo con quella della camera a ionizzazione con una scarto minore dello 0.1%. La risposta al variare delle UM è costante con una differenza entro lo 0.4%. L'analisi dei piani VMAT mostra valori di indice gamma per soglia 3%-3mm compresi tra 98.3%-100%, mentre per 2%-2mm i valori sono tra 93,5%-97,5%. Il Delta4+ risulta essere un sistema accurato in quanto l'incertezza ottenuta su tutte le misure non supera l'1%

Prevalence and Persistence of Breathing Disorders in Chronic Heart Failure Patients: Preliminary Results from Home Telemonitoring in the HHH Study

In this paper we present preliminary results of the European Community multicountry trial HHH (Home or Hospital in Heart Failure), which assessed the prevalence and persistence of nocturnal breathing disorders in mild-to-moderate CHF patients. All subjects (465) carried out a baseline respiratory recording in the hospital, followed by 12 recordings (one per month) at home. The latter were totally self-managed by the patients, and data were transmitted to the referring hospital through telephone lines. We found that 43 % of the patients had a periodic breathing pattern (PB, waxing and waning of ventilation with or without apneas) during the night lasting ≥ 1 hour, and the apnea-hypopnea index (AHI) was ≥ 5 events/hour in 51 % of them. During the 1-year follow-up, a PB ≥ 1 hour and an AHI ≥ 5 events/hour were persistent (i.e., occurred in> 50 % of the recordings) in 43 % and 52 % of the patients. These findings confirm the high prevalence of nocturnal breathing disorders in CHF patients and show that in a large proportion of patients they tend to persist over time. 1

Prevalence and persistence of breathing disorders in chronic heart failure patients: preliminary results from home telemonitoring in the HHH study

In this paper we present preliminary results of the European Community multicountry trial HHH (Home or Hospital in Heart Failure), which assessed the prevalence and persistence of nocturnal breathing disorders in mild-to-moderate CHF patients. All subjects (465) carried out a baseline respiratory recording in the hospital, followed by 12 recordings (one per month) at home. The latter were totally self-managed by the patients, and data were transmitted to the referring hospital through telephone lines. We found that 43% of the patients had a periodic breathing pattern (PB, waxing and waning of ventilation with or without apneas) during the night lasting ≥1 hour, and the apnea-hypopnea index (AHI) was ≥5 events/hour in 51% of them. During the 1-year follow-up, a PB ≥ 1 hour and an AHI ≥ 5 events/hour were persistent (i.e., occurred in > 50% of the recordings) in 43% and 52% of the patients. These findings confirm the high prevalence of nocturnal breathing disorders in CHF patients and show that in a large proportion of patients they tend to persist over time. © 2005 IEEE

Pulmonary Hypertension in Elderly Patients with Diastolic Dysfunction and Preserved Ejection Fraction

Abstract: Purpose: Patients with diastolic dysfunction may have a disproportionate degree of elevation in pulmonary pressure, particularly in the elderly. Higher pulmonary vascular resistance in the elderly patients with heart failure but preserved ejection fraction suggests that beyond the post-capillary contribution of pulmonary venous congestion, a pre-capillary component of pulmonary arterial hypertension occurs. We aim to identify if pulmonary vascular resistance in elderly patients with diastolic dysfunction is disproportionately higher than patients with systolic dysfunction independent of filling pressures. Methods: 389 patients identified retrospectively between 2003- 2010; elderly with preserved ejection fraction, elderly with depressed ejection fraction, and primary arterial hypertension who underwent right-heart catheterization at Rush University. Results: No significant difference in pulmonary vascular resistance between systolic and diastolic dysfunction. The mean difference in pulmonary vascular resistance was not statistically significant at 0.40 mmHg·min/l (95 % CI-3.03 to 3.83) with similar left ventricular filling pressures with mean difference of 3.38 mmHg (95 % CI,-1.27 to 8.02). When adjusted for filling pressures, there remained no difference in pulmonary vascular resistance for systolic and diastolic dysfunction. The mean pulmonary vascular resistance is more elevated in systolic heart failure compared to diastolic heart failure with means 3.13 mmHg·min/l and 3.52 mmHg·min/l, respectively

Second-line eribulin in triple negative metastatic breast cancer patients. Multicentre retrospective study: The tetris trial

Introduction: Large and consistent evidence supports the use of eribulin mesylate in clinical practice in third or later line treatment of metastatic triple negative breast cancer (mTNBC). Conversely, there is paucity of data on eribulin efficacy in second line treatment. Methods: We investigated outcomes of 44 mTNBC patients treated from 2013 through 2019 with second line eribulin mesylate in a multicentre retrospective study involving 14 Italian oncologic centres. Results: Median age was 51 years, with 11.4% of these patients being metastatic at diagnosis. Median overall survival (OS) and progression free survival (PFS) from eribulin starting were 11.9 (95%CI: 8.4-15.5) and 3.5 months (95%CI: 1.7-5.3), respectively. We observed 8 (18.2%) partial responses and 10 (22.7%) patients had stable disease as best response. A longer PFS on previous first line treatment predicted a better OS (HR=0.87, 95%CI: 0.77-0.99, p= 0.038) and a longer PFS on eribulin treatment (HR=0.92, 95%CI: 0.85-0.98, p=0.018). Progression free survival to eribulin was also favorably influenced by prior adjuvant chemotherapy (HR=0.44, 95%CI: 0.22-0.88, p=0.02). Eribulin was generally well tolerated, with grade 3-4 adverse events being recorded in 15.9% of patients. Conclusions: The outcomes described for our cohort are consistent with those reported in the pivotal Study301 and subsequent observational studies. Further data from adequately-sized, ad hoc trials on eribulin use in second line for mTNBC are warranted to confirm our findings